Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Trastuzumab containing regimens for early breast cancer

Información

DOI:
https://doi.org/10.1002/14651858.CD006243.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 18 abril 2012see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Cáncer de mama

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Lorenzo Moja

    Correspondencia a: Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

    [email protected]

  • Ludovica Tagliabue

    Medical Staff Directory, San Luca Hospital, Auxologic Institute, Milan, Italy

  • Sara Balduzzi

    Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy

  • Elena Parmelli

    Department of Epidemiology, Lazio Regional Health Service - ASL Roma1, Rome, Italy

  • Vanna Pistotti

    Cochrane Italy and IRCCS Mario Negri Institute for Pharmacological Research, Milan, Italy

  • Valentina Guarneri

    Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IRCCS, Padova, Italy

  • Roberto D'Amico

    Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy

Contributions of authors

Study concept: RD, LM.
Study protocol: RD, LM.
Search Strategy: VP.
Selection of studies: SB, LM, EP, LT.
Acquisition of data: SB, EP, LT.
Risk of bias assessment: SB, RD, LM, EP, LT.
Analysis of data: SB, RD, LM, EP.
Drafting of the manuscript: RD, LM, LT.

Interpretation and critical revision of the manuscript for important intellectualcontent: SB, RD, VG, LM, LT, EP, VP.

Sources of support

Internal sources

  • Mario Negri Institute for Pharmacological Research, Milan, Italy

  • Italian Cochrane Centre, Milan, Italy

  • University of Modena and Reggio‐Emilia, Modena, Italy

  • University of Milan, Italy

External sources

  • Italian Medicines Agency (AIFA ‐ Agenzia Italiana del Farmaco) ‐ CUP H95E07000130005, Italy

Declarations of interest

None known.

Acknowledgements

The authors are grateful to Cinzia Brambilla and Anna Compagnoni who assisted during the early stages of this systematic review; Su Golder and Carol Lefebvre for valuable suggestions about bibliographic searches; Deirdre Price, Jessica Thomas and Andrew Herxheimer for valuable suggestions about methodological issues in analysing adverse events; Davina Ghersi, Sharon Parker, Nancy Owens and Nicholas Wilcken for their helpful assistance during all the phases of the preparation of the protocol; and Judith Baggott who helped with copy‐editing this review.

Version history

Published

Title

Stage

Authors

Version

2012 Apr 18

Trastuzumab containing regimens for early breast cancer

Review

Lorenzo Moja, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri, Roberto D'Amico

https://doi.org/10.1002/14651858.CD006243.pub2

2006 Oct 18

Trastuzumab containing regimens for early breast cancer

Protocol

Lorenzo Moja, Cinzia Brambilla, Anna Compagnoni, Vanna Pistotti

https://doi.org/10.1002/14651858.CD006243

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.